Amendment No. 3 to Consulting Services Agreement between Vistagen Therapeutics, Inc. and FitzPatrick & Co. LLC
Vistagen Therapeutics, Inc. and FitzPatrick & Co. LLC have agreed to extend the term of their existing Consulting Services Agreement. This amendment, effective July 1, 2023, continues the agreement until December 31, 2023. All other terms of the original agreement remain unchanged and in effect. Both parties have signed to confirm their acceptance of this extension.
Exhibit 10.159
AMENDMENT NO. 3
TO
CONSULTING SERVICES AGREEMENT
This Amendment (“Amendment No. 3”) is made between Vistagen Therapeutics, Inc., a Nevada corporation having an address at 343 Allerton Avenue, South San Francisco, California 94080 (“Vistagen”), and FitzPatrick & Co. LLC, a Delaware limited liability company, having an address at 2023 Allen Place, NW, Washington DC 20009 (“Consultant”), effective as of July 1, 2023.
WHEREAS, Vistagen and Consultant entered into a Consulting Services Agreement dated January 21, 2022, Amendment No. 1 to the Consulting Agreement dated June 1, 2022, and Amendment No. 2 to the Consulting Agreement dated January 1, 2023 (collectively, the “Agreement”); and
WHEREAS, the parties wish to amend the Agreement to extend its term.
Vistagen and Consultant, therefore, agree as follows:
AMENDMENT
| 1. | The term of this Agreement shall be extended and continue until December 31, 2023. |
Except as expressly provided in this Amendment No. 3, the Agreement remains unchanged and in full force and effect.
[Remainder of page intentionally left blank]
Each party is signing this agreement with the party’s authorized signature.
| AGREED TO: | AGREED TO: | |||
| VISTAGEN THERAPEUTICS, INC. | FITZPATRICK & CO., LLC | |||
| By: | /s/ Shawn K. Singh | By: | /s/ Maggie FitzPatrick | |
| Name: | Shawn K. Singh, J.D. | Name: | Margaret Mary FitzPatrick | |
| Title: | Chief Executive Officer | Title: | Managing Director | |
| Date: | June 22, 2023 | Date: | June 22, 2023 | |
